AbbVie (NYSE:ABBV) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket.
Alkermes plc (NASDAQ:ALKS) initiated with Neutral rating and $19 (flat) price target at Mizuho.
BioLife Solutions (NASDAQ:BLFS) initiated with Buy rating and $27 (89% upside) price target at B. Riley FBR.
Biohaven Pharmaceutical Holding (NYSE:BHVN) initiated with Buy rating and $62 (15% upside) price target at Mizuho.
Karuna Therapeutics (NASDAQ:KRTX) initiated with Buy rating and $120 (22% upside) at Mizuho.
Kodiak Sciences (NASDAQ:KOD) initiated with Buy rating and $101 (56% upside) price target at SunTrust.
Eli Lilly (NYSE:LLY) initiated with Neutral rating and $148 (flat) price target at Mizuho.
Neurocrine Biosciences (NASDAQ:NBIX) initiated with Neutral rating at Mizuho.
Pfizer (NYSE:PFE) initiated with Buy rating and $42 (10% upside) price target at Mizuho. Shares up 1% premarket.
Sage Therapeutics (NASDAQ:SAGE) initiated with Neutral rating at Mizuho.
Satsuma Pharmaceuticals (NASDAQ:STSA) initiated with Buy rating and $37 (56% upside) price target at Mizuho.
Tandem Diabetes Care (NASDAQ:TNDM) initiated with Outperform rating and $85 (14% upside) price target at Raymond James.
Voyager Therapeutics (NASDAQ:VYGR) initiated with Outperform rating and $26 (105% upside) price target at Oppenheimer.
Gilead Sciences (NASDAQ:GILD) downgraded to Market Perform with a $70 (6% upside) price target at Bernstein. Shares up 2% premarket.
https://seekingalpha.com/news/3539113-mizuho-likes-abbvie-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.